Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PET imaging study of single-dose fluciclovine (18F) in prostate cancer
jRCT2080221289Phase 2Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Nov 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Safety of a single intravenous dose of fluciclovine (18F) (NMK36) and Efficacy of fluciclovine (18F) PET for lesion delineation. Started Nov 2010; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080221289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221289.